Home

Micro Interventional Devices chairman, president and CEO, Michael Whitman, and Oscor president and CEO Thomas Osypka, are pleased to announce a strategic alliance that leverages each company’s unique strengths and capabilities to further develop and commercialize innovative solutions to structural heart disease, specifically, Micro Interventional Devices’ MIA—minimally invasive annuloplasty—technology.

According to a press release, Micro Interventional Devices designs, develops and commercialises proprietary, percutaneous technologies solving unmet needs in structural heart disease. Oscor designs, develops, manufactures and markets a variety of highly specialised implantable devices for neuromodulation, cardiac rhythm management and structural heart disease, as well as ancillary delivery systems and accessories. Additionally, it offers its extensive portfolio of intellectual property to its customers under Contract Manufacturing or OEM branding.

Under the terms of this agreement, Micro Interventional Devices acquires a non-exclusive worldwide license to Oscor’s patented catheter technology and in turn, Oscor receives exclusive manufacturing rights to Micro Interventional Devices’ MIA devices. The synergy accelerates Micro Interventional Devices’ corporate development and provides access to a world-class backend organization with an established regulatory and distribution network.

In conjunction with the strategic alliance, Micro Interventional Devices is closing a US$20 million series D round of financing led by Oscor. Also participating are Originate Ventures, LifeSciences Greenhouse of PA, Ben Franklin Venture Partners of Northeastern PA, and other existing MID shareholders. In this transaction, Micro Interventional Devices debt will convert to Series D preferred stock. Oscor CEO, Thomas Osypka will join Micro Interventional Devices’ board of directors (effective March 2019).

Micro Interventional Devices will use the proceeds to complete its ongoing STTAR Clinical Trial. STTAR, the study of transcatheter tricuspid annular repair, is studying MIA’s safety and efficacy in the percutaneous (less invasive) treatment of tricuspid and mitral regurgitation. Tricuspid and mitral regurgitation affects an estimated 12 million people worldwide. Eight patients have already been enrolled in the STTAR trial to date with encouraging results.

Whitman comments: “We are excited to be entering into this agreement with Oscor. Under Thomas’ guidance, Oscor has been designing, developing and manufacturing sophisticated catheter technologies for over 20 years. Partnering with Oscor will enable Micro Interventional Devices to rapidly and thoroughly complete MIA’s technical dossier, which is a requirement for CE mark approval. Additionally, we now have the ability to ramp up production to serve this very large patient population who currently has no real treatment options.”

Source CardiovascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: Micro Interventional Devices enters strategic alliance with Oscor

Chia sẽ qua google bài: Micro Interventional Devices enters strategic alliance with Oscor

Chia sẽ qua twitter bài: Micro Interventional Devices enters strategic alliance with Oscor

Chia sẽ qua MySpace bài: Micro Interventional Devices enters strategic alliance with Oscor

Chia sẽ qua LinkedIn bài: Micro Interventional Devices enters strategic alliance with Oscor

Chia sẽ qua stumbleupon bài: Micro Interventional Devices enters strategic alliance with Oscor

Chia sẽ qua icio bài: Micro Interventional Devices enters strategic alliance with Oscor

Chia sẽ qua digg bài: Micro Interventional Devices enters strategic alliance with Oscor

Chia sẽ qua yahoo bài: Micro Interventional Devices enters strategic alliance with Oscor

Tin tức liên quan

Vesteck completes first-in-human use of several Suture-Tight devices

Age is just a number: Individual patient data meta-analysis probes safety of CEA in the elderly

Artificial intelligence can predict risk of complications after endovascular aneurysm repair

Bluegrass Vascular announces Journal of Vascular Surgery paper reporting use of Surfacer system

Vascular access creation: EndoAVF keeps future options open, but is not a replacement for surgical fistulas

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.